EA199900939A1 - Остеопротегерин-связывающие белки и рецепторы - Google Patents

Остеопротегерин-связывающие белки и рецепторы

Info

Publication number
EA199900939A1
EA199900939A1 EA199900939A EA199900939A EA199900939A1 EA 199900939 A1 EA199900939 A1 EA 199900939A1 EA 199900939 A EA199900939 A EA 199900939A EA 199900939 A EA199900939 A EA 199900939A EA 199900939 A1 EA199900939 A1 EA 199900939A1
Authority
EA
Eurasian Patent Office
Prior art keywords
osteoprotegerin
receptors
polypeptide
binding protein
producing
Prior art date
Application number
EA199900939A
Other languages
English (en)
Other versions
EA003636B1 (ru
Inventor
Уильям Дж. Бойл
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27368158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199900939(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/842,842 external-priority patent/US5843678A/en
Priority claimed from US09/052,521 external-priority patent/US6316408B1/en
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA199900939A1 publication Critical patent/EA199900939A1/ru
Publication of EA003636B1 publication Critical patent/EA003636B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Описан новый полипептид, остеопротегерин-связывающий белок, вовлеченный в созревание остеокластов. Белок идентифицирован на основе его аффинности к остеопротегерину. Также описаны последовательности нуклеиновых кислот, кодирующих полипептид или его фрагмент, аналог или производное, векторы и клетки-хозяева для получения полипептида, способы получения остеопротегерин-связывающего белка и исследования по связыванию. Изобретение также относится к композициям, способам лечения заболеваний костей, например остеопороза, потери костной массы при артритах и метастазисе, гиперкальциемии и болезни Педжета, и рецепторам остеопротегерин-связывающего белка. Рецепторы, агонисты и антагонисты могут быть использованы для лечения заболеваний костей.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900939A 1997-04-16 1998-04-15 Остеопротегеринсвязующие белки и рецепторы EA003636B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/842,842 US5843678A (en) 1997-04-16 1997-04-16 Osteoprotegerin binding proteins
US88085597A 1997-06-23 1997-06-23
US09/052,521 US6316408B1 (en) 1997-04-16 1998-03-30 Methods of use for osetoprotegerin binding protein receptors
PCT/US1998/007584 WO1998046751A1 (en) 1997-04-16 1998-04-15 Osteoprotegerin binding proteins and receptors

Publications (2)

Publication Number Publication Date
EA199900939A1 true EA199900939A1 (ru) 2000-08-28
EA003636B1 EA003636B1 (ru) 2003-08-28

Family

ID=27368158

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900939A EA003636B1 (ru) 1997-04-16 1998-04-15 Остеопротегеринсвязующие белки и рецепторы

Country Status (28)

Country Link
US (1) US7923008B2 (ru)
EP (2) EP1717315A3 (ru)
JP (2) JP2001526532A (ru)
CN (1) CN1264427A (ru)
AT (1) ATE363533T1 (ru)
AU (4) AU743257B2 (ru)
BG (1) BG65242B1 (ru)
BR (1) BR9808545A (ru)
CA (1) CA2285746C (ru)
CZ (1) CZ302262B6 (ru)
DE (1) DE69837845T3 (ru)
DK (1) DK0975754T4 (ru)
EA (1) EA003636B1 (ru)
EE (1) EE05496B1 (ru)
ES (1) ES2284203T5 (ru)
HK (1) HK1022330A1 (ru)
HU (1) HU230547B1 (ru)
ID (1) ID23855A (ru)
IL (1) IL132304A0 (ru)
NO (1) NO325175B1 (ru)
NZ (1) NZ500253A (ru)
PL (1) PL190092B1 (ru)
RO (1) RO128635A2 (ru)
SI (1) SI0975754T2 (ru)
SK (1) SK288559B6 (ru)
TR (1) TR199902512T2 (ru)
TW (1) TW589376B (ru)
WO (1) WO1998046751A1 (ru)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
DE122010000046I1 (de) * 1996-12-13 2011-05-05 Schering Corp Oberflächenantigene aus Säugern
EP2371962A3 (en) * 1996-12-23 2011-12-21 Immunex Corporation Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
AU2008200700C1 (en) * 1997-04-15 2013-04-04 Daiichi Sankyo Co., Ltd Novel Protein and Process for Producing The Same
EP0911342B2 (en) 1997-04-15 2013-05-22 Daiichi Sankyo Company, Limited Novel protein and process for producing the same
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
JP2001526532A (ja) 1997-04-16 2001-12-18 アムジエン・インコーポレーテツド オステオプロテゲリン結合性蛋白および受容体
ATE412746T1 (de) * 1998-05-14 2008-11-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
ES2239457T3 (es) 1998-09-15 2005-09-16 Pharmexa A/S Procedimiento para regular a niveles mas bajos la actividad de ligando de osteoprotegerina.
EP1541587A3 (en) * 1998-09-15 2007-06-20 Pharmexa A/S Method for down-regulating osteoprotegerin ligand activity
AU773891C (en) 1998-10-23 2005-02-17 Kirin-Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
MXPA01013236A (es) 1999-06-28 2002-06-21 Genentech Inc Metodos para hacer ligando apo-2 mediante el uso de iones metalicos divalentes.
MXPA02001665A (es) 1999-08-17 2003-07-14 Biogen Inc Receptor de baff (bcma) como agente inmunorregulador.
AU7615600A (en) * 1999-09-27 2001-04-30 Eli Lilly And Company Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
ATE329610T1 (de) 2000-02-16 2006-07-15 Genentech Inc Anti-april antikörper und hybridomazellen
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
CA2400929C (en) † 2000-02-23 2011-05-31 Amgen Inc. Antagonistic selective binding agents of osteoprotegerin binding protein
US6600018B1 (en) 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
EP1272647B1 (en) 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
DE60136816D1 (de) 2000-07-27 2009-01-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
AU2001286586A1 (en) * 2000-08-18 2002-03-04 University Of Massachusetts Medical Center Trance regulation of chondrocyte differentiation
CA2423052C (en) 2000-09-22 2011-07-12 Immunex Corporation Screening assays for agonists or antagonists of receptor activator of nf-kb
WO2002055547A2 (en) 2001-01-10 2002-07-18 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Sfrp and peptide motifs that interact with sfrp and methods of their use
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
DK2295081T3 (en) * 2001-06-26 2019-02-18 Amgen Inc Antibodies to OPGL
DK1409544T3 (da) 2001-07-03 2009-10-26 Genentech Inc Humane DR4-antistoffer og anvendelser deraf
IL161051A0 (en) 2001-10-02 2004-08-31 Genentech Inc Apo-2 ligand variants and uses thereof
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
PT1450847E (pt) 2001-11-13 2011-01-05 Genentech Inc Formulações de ligando de apo2/trail e suas utilizações
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
AU2011265413B2 (en) * 2002-04-05 2014-04-10 Amgen Inc. Human Anti-OPGL Neutralizing Antibodies as Selective OPGL, Pathway Inhibitors
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
JP4574350B2 (ja) 2002-06-24 2010-11-04 ジェネンテック， インコーポレイテッド Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法
CA2508773C (en) 2002-12-10 2013-08-27 Schering-Plough Ltd. Canine rankl and methods for preparing and using the same
JP2008505928A (ja) 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド 治療用ペプチド
JP5237638B2 (ja) 2004-08-06 2013-07-17 ジェネンテック， インコーポレイテッド バイオマーカーを用いたアッセイおよび方法
ATE508753T1 (de) 2004-08-06 2011-05-15 Genentech Inc Assays und verfahren unter verwendung von biomarkern
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1915625B1 (en) 2005-08-16 2012-01-04 Genentech, Inc. Apoptosis sensitivity to apo2l/trail by testing for galnac-t14 expression in cells/tissues
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2117572A4 (en) * 2006-12-22 2010-03-31 Univ California NOVEL FUSION MOLECULE BASED ON A NEW TAA VARIANT
JP5591691B2 (ja) 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド 生物活性を有する融合タンパク質を作製するための組成物及び方法
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
JP2010538244A (ja) * 2007-06-20 2010-12-09 ガラパゴス・ナムローゼ・フェンノートシャップ 骨及び関節の変性疾患の治療に有用な分子標的及び化合物並びにその同定方法
KR101661940B1 (ko) * 2008-05-02 2016-10-04 고쿠리츠 다이가쿠 호진 교토 다이가쿠 핵 초기화 방법
AU2009319864A1 (en) 2008-11-25 2011-07-14 Biogen Idec Ma Inc. Use of DR6 and P75 antagonists to promote survival of cells of the nervous system
EP2434285A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer diagnostics
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
JP2015514686A (ja) 2012-02-29 2015-05-21 コヨーテ・ファーマシューティカルズ・インコーポレイテッドＣｏｙｏｔｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｇａ及びそのｇｇａ誘導体組成物並びにこれらを含む麻痺状態を含めた神経変性疾患を治療する方法
US9119808B1 (en) 2012-10-08 2015-09-01 Coyote Pharmaceuticals, Inc. Treating neurodegenerative diseases with GGA or a derivative thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
AU2014318017B2 (en) 2013-09-05 2020-02-06 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
EP3467501B1 (en) 2014-05-16 2020-11-04 Amgen Inc. Assay for detecting th1 and th2 cell populations
EP3574017A1 (en) 2017-01-27 2019-12-04 Kymab Limited Anti-opg antibodies
SG11201908328XA (en) 2017-03-14 2019-10-30 Amgen Inc Control of total afucosylated glycoforms of antibodies produced in cell culture
KR20200104298A (ko) 2017-11-22 2020-09-03 인바이오모션 에스.엘. c-MAF 상태에 기반한 유방암의 요법 치료
EA202092286A1 (ru) 2018-03-26 2021-03-18 Эмджен Инк. Общие афукозилированные гликоформы антител, полученные в культуре клеток
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
CN113621060B (zh) * 2020-05-07 2023-07-04 浙江瑞硕生物技术有限公司 一种opg抗体对及其应用
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
MX2023004364A (es) 2020-10-15 2023-05-03 Amgen Inc Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CA3233279A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4710457A (en) 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en) 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
WO1992009697A1 (en) 1990-11-30 1992-06-11 Celtrix Laboratories, Inc. USE OF A BONE MORPHOGENETIC PROTEIN IN SYNERGISTIC COMBINATION WITH TGF-β FOR BONE REPAIR
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
MX9204303A (es) 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
PT639079E (pt) 1992-04-30 2000-04-28 Amgen Inc Composicao para tratamento de doencas mediadas por interleuquina-1 e factor de necrose tumoral
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5578569A (en) 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
ATE202571T1 (de) 1993-09-14 2001-07-15 Merck & Co Inc Humane protein-tyrosinphosphatase decodierende cdna
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
US5641747A (en) 1994-07-25 1997-06-24 Temple University-Of The Commonwealth System Of Higher Education Treatment of osteopetrotic diseases
DE69434988T2 (de) * 1994-11-07 2008-03-06 Human Genome Sciences, Inc. Tumornekrose-faktor-gamma
AU4440496A (en) 1995-02-10 1996-08-22 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7094564B1 (en) 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US20030166097A1 (en) * 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
WO1997000318A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
WO1997000317A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
KR100510234B1 (ko) * 1995-06-29 2005-11-25 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6046048A (en) 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US5981220A (en) * 1996-03-27 1999-11-09 Human Genome Sciences, Inc. Epidermal differentiation factor
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
DE122010000046I1 (de) 1996-12-13 2011-05-05 Schering Corp Oberflächenantigene aus Säugern
AU5901598A (en) 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
FR2757507B1 (fr) 1996-12-20 1999-01-29 Inst Francais Du Petrole Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation
EP2371962A3 (en) 1996-12-23 2011-12-21 Immunex Corporation Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
EP0911342B2 (en) * 1997-04-15 2013-05-22 Daiichi Sankyo Company, Limited Novel protein and process for producing the same
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
JP2001526532A (ja) 1997-04-16 2001-12-18 アムジエン・インコーポレーテツド オステオプロテゲリン結合性蛋白および受容体
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
WO1998049305A1 (en) 1997-05-01 1998-11-05 Amgen Inc. Chimeric opg polypeptides
AU7705098A (en) 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
ATE412746T1 (de) * 1998-05-14 2008-11-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
ES2239457T3 (es) * 1998-09-15 2005-09-16 Pharmexa A/S Procedimiento para regular a niveles mas bajos la actividad de ligando de osteoprotegerina.
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
AU6788900A (en) 1999-09-03 2001-04-10 Amgen, Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
CA2400929C (en) 2000-02-23 2011-05-31 Amgen Inc. Antagonistic selective binding agents of osteoprotegerin binding protein
AU2001286586A1 (en) 2000-08-18 2002-03-04 University Of Massachusetts Medical Center Trance regulation of chondrocyte differentiation
CA2423052C (en) * 2000-09-22 2011-07-12 Immunex Corporation Screening assays for agonists or antagonists of receptor activator of nf-kb
EP1399175A4 (en) 2001-05-17 2005-11-30 Immunex Corp THERAPEUTIC USE OF RANK ANTAGONISTS
CA2449658A1 (en) * 2001-06-06 2002-12-12 Immunex Corporation Use of rank antagonists to treat cancer
DK2295081T3 (en) * 2001-06-26 2019-02-18 Amgen Inc Antibodies to OPGL
US6753755B2 (en) * 2001-06-28 2004-06-22 Safer Home, Inc. Electrical safety connector fuse
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US6592001B2 (en) * 2001-12-18 2003-07-15 Kimberly-Clark Worldwide Dispenser for sheet material containing a dispensing port incrementally variable within a range
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US7706431B2 (en) * 2005-06-30 2010-04-27 Nokia Corporation System and method for providing optimized receiver architectures for combined pilot and data signal tracking

Also Published As

Publication number Publication date
JP5001758B2 (ja) 2012-08-15
JP2008054682A (ja) 2008-03-13
AU7120598A (en) 1998-11-11
AU2008202516A1 (en) 2008-06-26
US7923008B2 (en) 2011-04-12
US20060246064A1 (en) 2006-11-02
DK0975754T3 (da) 2007-10-01
TW589376B (en) 2004-06-01
NO325175B1 (no) 2008-02-11
EP0975754A1 (en) 2000-02-02
EP1717315A2 (en) 2006-11-02
EP0975754B1 (en) 2007-05-30
TR199902512T2 (xx) 2000-06-21
HUP0001400A3 (en) 2001-12-28
NZ500253A (en) 2002-09-27
BG65242B1 (bg) 2007-09-28
RO128635A2 (ro) 2013-07-30
DE69837845T2 (de) 2008-01-31
CZ359899A3 (cs) 2000-02-16
SK141999A3 (en) 2000-05-16
BG103824A (en) 2000-05-31
IL132304A0 (en) 2001-03-19
EA003636B1 (ru) 2003-08-28
SI0975754T1 (sl) 2007-10-31
SK288559B6 (sk) 2018-05-02
HK1022330A1 (en) 2000-08-04
EP1717315A3 (en) 2007-06-20
SI0975754T2 (sl) 2016-04-29
AU2005201799B2 (en) 2008-06-12
AU2005201799A1 (en) 2005-05-26
DK0975754T4 (en) 2016-03-21
PL190092B1 (pl) 2005-10-31
ID23855A (id) 2000-05-25
DE69837845D1 (de) 2007-07-12
BR9808545A (pt) 2000-05-23
CA2285746C (en) 2010-09-28
AU9523401A (en) 2002-01-24
EP0975754B2 (en) 2016-01-06
AU743257B2 (en) 2002-01-24
ES2284203T5 (es) 2016-03-11
DE69837845T3 (de) 2016-06-23
WO1998046751A1 (en) 1998-10-22
AU779461B2 (en) 2005-01-27
EE9900611A (et) 2000-08-15
CA2285746A1 (en) 1998-10-22
PL336311A1 (en) 2000-06-19
HUP0001400A2 (en) 2000-07-28
HU230547B1 (hu) 2016-11-28
CZ302262B6 (cs) 2011-01-19
ES2284203T3 (es) 2007-11-01
EE05496B1 (et) 2011-12-15
JP2001526532A (ja) 2001-12-18
ATE363533T1 (de) 2007-06-15
CN1264427A (zh) 2000-08-23
NO995044L (no) 1999-12-15
NO995044D0 (no) 1999-10-15
AU779461C (en) 2005-10-13

Similar Documents

Publication Publication Date Title
EA199900939A1 (ru) Остеопротегерин-связывающие белки и рецепторы
EP2311955A3 (en) Osteoprotegerin binding proteins and their receptors
FÜrst et al. Mammalian skeletal muscle C-protein: purification from bovine muscle, binding to titin and the characterization of a full-length human cDNA
DE69535641D1 (de) Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
WO2003038063A3 (en) Human secreted proteins
WO2001055364A3 (en) Nucleic acids, proteins, and antibodies
BR9814335A (pt) Proteìna, exceto as existentes ao natural, polinucleotìdeo substancialmente puro, anticorpo elaborado por um processo que compreende a etapa de injetar uma preparação farmaceuticamente aceitável, vetor para expressar o drr-1 de rato, vetor, célula hospedeira drr-1 de rato, drr-1 de ser humano, drr-2 de ser humano, drr-3 de ser humano, drr-4 de ser humano, drr-5 de ser humano, drr-6 de ser humano recombinantes, e, processo para ensaiar um composto de teste quanto à sua capacidade para ligar-se a ou para ativar um receptor especìfico de gânglios da raiz dorsal ligado à proteìna g (drr)
ATE342359T1 (de) Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
IL193149A (en) Anti il-17c antibody and therapeutic compositions comprising same
WO2001054472A3 (en) Nucleic acids, proteins, and antibodies
WO2002092787A3 (en) Human secreted proteins
ATE323764T1 (de) Kappa/mu ähnliche proteintyrosinphosphatase, proteintyrosinphosphatase lambda
WO1996031603A3 (en) Methods and compositions for regulating fadd
ATE190318T1 (de) Pcna bindende substanz
SE9602822D0 (sv) New receptor
ATE331032T1 (de) Glutamine: fructose-6-phosphat amidotransferase (gfat), ihre herstellung und verwendung
Lowey et al. Neonatal and adult myosin heavy chains form homodimers during avian skeletal muscle development.
WO2000031262A3 (en) Human neurotensin subtype 2 receptor
WO2004042000A3 (en) 157 human secreted proteins
WO1999063094A3 (en) Nucleotide and protein sequences of gpr1 and methods based thereon
SE9604439D0 (sv) New receptor
Bolyard et al. Mutagenesis of human fibrinogen γ chain 259–411 synthesized in E. coli: Further characterization of the role of the disulfide bond CYS326–CYS339 in calcium binding
Siffroi-Fernandez et al. Identification of thyroglobulin domain (s) involved in cell-surface binding and endocytosis
WO2001055167A8 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
ND4A Extension of term of a eurasian patent
ND4A Extension of term of a eurasian patent
ND4A Extension of term of a eurasian patent
ND4A Extension of term of a eurasian patent
ND4A Extension of term of a eurasian patent
MK4A Patent expired

Designated state(s): KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ